FFPE tissue for oncology research: blocks, slides, curls and control tissue
Source FFPE tumor blocks, unstained FFPE slides, FFPE tissue sections and curls with linked clinical and molecular data. Select primary tumors, metastases or normal tissue around your indication, treatment history and biomarker requirements. Tissue, format and data availability are reviewed for your cohort. Add IHC or RNAscope to your tissue request and work with one point of contact, from case selection through staining and pathologist scoring.
GCLP-accredited laboratories · ISO 9001 certified
HBS & DONOR DATA
Quality biospecimens & data for precision medicine
Tissue for your cohort
Select the tissue type around your indication and study requirements.
FFPE samples for your workflow
Work with our team to define the preparation and quantity your assay requires.
UK · Italy · France · GCLP-accredited laboratories · ISO 9001 certified
Donors from participating medical centers, with informed consent and ethics approval.
Breadth of donor profiles
Specimen, treatment, outcomes and molecular data, structured at the patient level.
Patient trajectory
- Primary tumors & matched distant metastases
- Matched normal tissue
- Neoadjuvant & adjuvant treatment
- Standard-of-care targeted therapies & checkpoint inhibitors
- Treatment regimen, line & dates
- Responders & non-responders
Structured outcomes
- Clinician-recorded response
- Overall survival (months)
- Progression-free survival (months)
- Time to events (months)
- Last follow-up
- Event flags: recurrence / death / composite
Molecular characterization
- IHC
- FISH
- RNA-ISH
- NGS: SNVs, CNVs & fusions
Records are fully anonymized. Available fields vary by donor and reflect clinical practice at the source center. Cohorts are selected to meet your project’s requirements.
FFPE TISSUE COHORTS
Available FFPE cohorts
Explore 112 FFPE cohorts by tissue type, biomarker and treatment history. Find samples with the clinical and molecular data your study needs.
Normal tissue
Non-malignant bladder, breast, colon, liver, ovary and prostate tissue.
6FFPE
cohorts
31TMAs
Cholangiocarcinoma
Cholangiocarcinoma cohorts with follow-up or histopathology data.
2FFPE
cohorts
5TMAs
Gallbladder cancer
Gallbladder and extra-hepatic bile duct cancer with histopathology data.
1FFPE
cohort
2TMAs
Bladder cancer
Urothelial carcinoma with matched metastases, follow-up or matched double-spun plasma.
3FFPE
cohorts
16TMAs
Glioblastoma (GBM)
Glioblastoma with follow-up, IDH1/2, survival or MGMT data, as listed by cohort.
2FFPE
cohorts
7TMAs
Breast cancer
Breast cancer and TNBC cohorts with receptor, treatment, metastatic or matched-plasma information.
12FFPE
cohorts
27TMAs
Cervical cancer
Cervical adenocarcinoma and squamous cell carcinoma with follow-up data.
1FFPE
cohort
5TMAs
Colorectal cancer
Colorectal cancer cohorts with mutation, HER2, MSI, treatment, metastasis or matched-plasma data, plus colon adenoma.
12FFPE
cohorts
62TMAs
Endometrial cancer
Endometrial cohorts with follow-up, histopathology or matched double-spun plasma.
3FFPE
cohorts
13TMAs
Esophageal cancer
Esophageal adenocarcinoma and squamous cell carcinoma with matched metastases, follow-up or survival data.
3FFPE
cohorts
5TMAs
Gastric cancer
Gastric and GEJ cohorts with treatment, follow-up, matched metastases, survival or matched plasma.
7FFPE
cohorts
17TMAs
Head and neck cancer
Head and neck SCC with HPV/p16, follow-up, matched metastases or matched double-spun plasma.
6FFPE
cohorts
23TMAs
Renal cell carcinoma
Renal cell carcinoma with nivolumab follow-up, clinical follow-up, survival or matched plasma.
4FFPE
cohorts
14TMAs
Liver cancer (HCC)
HCC cohorts with histopathology, follow-up, survival or PD-L1 (22C3) data.
3FFPE
cohorts
11TMAs
Idiopathic pulmonary fibrosis (IPF)
Idiopathic pulmonary fibrosis with histopathology data.
1FFPE
cohort
1TMA
Lung cancer
NSCLC cohorts with histopathology, EGFR/KRAS, PD-L1, treatment, matching or optional datasets.
19FFPE
cohorts
53TMAs
Melanoma
Melanoma cohorts with treatment and follow-up information, including explicitly unmatched pre/post-treatment groups.
6FFPE
cohorts
15TMAs
Mesothelioma
Mesothelioma with histopathology data.
1FFPE
cohort
5TMAs
Ovarian cancer
Ovarian cohorts with serous histology, platinum-treatment information, selected BRCA status or matched plasma.
6FFPE
cohorts
18TMAs
Pancreatic cancer
Pancreatic cohorts with histopathology, metastases, follow-up or matched double-spun plasma.
5FFPE
cohorts
16TMAs
Prostate cancer
Prostate cohorts with HRPC, PSA, Gleason, treatment or matched-plasma information.
5FFPE
cohorts
22TMAs
Sarcoma
Fibrosarcoma, angiosarcoma and undifferentiated sarcoma.
1FFPE
cohort
6TMAs
Cutaneous SCC
Cutaneous squamous cell carcinoma with histopathology data.
1FFPE
cohort
4TMAs
Testicular cancer
Testicular cancer with histopathology data.
1FFPE
cohort
1TMA
Thyroid cancer
Thyroid cancer with follow-up data.
1FFPE
cohort
6TMAs
No matching cohorts. Try another term or discuss your requirements with our team.
Explore tissue and patient profiles
Find tissue around your diagnosis, biomarker and treatment criteria. Our team can help define the cohort for your study.
NSCLC · Patient profile
EGFR-mutated locally advanced or metastatic disease
NSCLC · Patient profile
EGFR-mutated, MET-positive locally advanced or metastatic disease
NSCLC · Patient profile
EGFR exon 20 insertion mutation
NSCLC · Patient profile
TKI-treatment-naïve ROS1-positive disease
NSCLC · Patient profile
Advanced or metastatic NSCLC
NSCLC · Patient profile
PD-L1 <50% metastatic NSCLC
NSCLC · Patient profile
PD-L1 tumor-cell expression ≥1% non-squamous NSCLC
NSCLC · Patient profile
PD-L1 tumor-cell expression ≥1% squamous NSCLC
NSCLC · Patient profile
PD-L1 tumor-cell expression ≥50% locally advanced or metastatic non-squamous NSCLC
NSCLC · Patient profile
Before or after immunotherapy / checkpoint inhibitor treatment
Breast cancer · Patient profile
TNBC across all stages, including metastatic disease
Breast cancer · Patient profile
Breast cancer stages I–III
Breast cancer · Patient profile
Before or after CDK4/6 inhibitor treatment
Breast cancer · Patient profile
BRCA1/2- or PALB2-mutated, HR-positive / HER2-negative advanced disease
Breast cancer · Patient profile
ER-positive / HER2-negative advanced disease
Breast cancer · Patient profile
HER2-negative, BRCA-mutated neoadjuvant cohorts
Breast cancer · Patient profile
HER2-positive metastatic disease
Colorectal cancer · Patient profile
Metastatic disease with MSS, MSI-H, KRAS, NRAS or BRAF profiles
Colorectal cancer · Patient profile
Microsatellite-stable (MSS) colorectal cancer
Colorectal cancer · Patient profile
dMMR / MSI-H colon cancer
Colorectal cancer · Patient profile
dMMR / MSI-H rectal cancer
Colorectal cancer · Patient profile
Left-sided KRAS/NRAS/BRAF wild-type disease
Colorectal cancer · Patient profile
Second-line KRAS/NRAS/BRAF wild-type disease with prior chemotherapy
Gastric / GEJ cancer · Patient profile
CLDN18.2-expressing advanced or metastatic gastric/GEJ adenocarcinoma
Gastric / GEJ cancer · Patient profile
HER2-positive locally advanced or metastatic gastric/GEJ adenocarcinoma
Gastric / GEJ cancer · Patient profile
Late-stage or metastatic gastric adenocarcinoma
Ovarian cancer · Patient profile
BRCA wild-type or BRCA-mutated advanced disease
Ovarian cancer · Patient profile
HER2 IHC 3+, 2+ or 1+ advanced high-grade epithelial disease
Ovarian cancer · Patient profile
Platinum-resistant or platinum-sensitive disease
Ovarian cancer · Patient profile
Recurrent ovarian cancer
Prostate cancer · Patient profile
Metastatic prostate cancer
Prostate cancer · Patient profile
Metastatic castration-resistant prostate cancer (mCRPC)
Prostate cancer · Patient profile
mCRPC with prior taxane exposure
Prostate cancer · Patient profile
PSMA-positive mCRPC
Prostate cancer · Patient profile
Neuroendocrine prostate carcinoma
Bladder / urothelial cancer · Patient profile
Cisplatin-eligible or cisplatin-ineligible muscle-invasive disease
Bladder / urothelial cancer · Patient profile
Non-muscle-invasive bladder cancer
Endometrial cancer · Patient profile
B7-H4-expressing cohorts
Endometrial cancer · Patient profile
HER2 IHC 3+ or 2+ cohorts
Endometrial cancer · Patient profile
Mismatch repair-proficient (MMRp) disease
Endometrial cancer · Patient profile
Stage III/IV or recurrent disease
Pancreatic adenocarcinoma · Patient profile
Metastatic pancreatic ductal adenocarcinoma
Head & neck SCC · Patient profile
Platinum-eligible locally advanced HNSCC
Head & neck SCC · Patient profile
Metastatic HNSCC
Head & neck SCC · Patient profile
Before or after immunotherapy / checkpoint inhibitor treatment
Melanoma · Patient profile
Resectable stage III/IV melanoma
Melanoma · Patient profile
Before or after immunotherapy / checkpoint inhibitor treatment
Renal cell carcinoma · Patient profile
Stage III/IV or metastatic disease
Renal cell carcinoma · Patient profile
Clear-cell renal cell carcinoma (ccRCC)
Renal cell carcinoma · Patient profile
Before or after immunotherapy / checkpoint inhibitor treatment
Hepatocellular carcinoma · Patient profile
Adjuvant cohorts
Hepatocellular carcinoma · Patient profile
Neoadjuvant cohorts
Hepatocellular carcinoma · Patient profile
Stage III/IV or metastatic disease
Hepatocellular carcinoma · Patient profile
GPC3-positive hepatocellular carcinoma
Esophageal cancer · Patient profile
Advanced disease with longitudinal data
Small-cell lung cancer · Patient profile
Relapsed / refractory small-cell lung cancer
Small-cell lung cancer · Patient profile
Extensive-stage small-cell lung cancer
Neuroendocrine carcinoma · Patient profile
Poorly differentiated neuroendocrine carcinoma, including SCLC, large-cell neuroendocrine carcinoma (LCNEC) and extrapulmonary NEC
Non-Hodgkin lymphoma · Patient profile
Discuss the required subtype, tissue and associated data.
Cutaneous squamous cell carcinoma · Patient profile
Early-stage cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinoma · Patient profile
Stage II–IV cutaneous squamous cell carcinoma
Glioblastoma · Patient profile
Recurrent glioblastoma (GBM)
Gastrointestinal stromal tumors · Patient profile
Gastrointestinal stromal tumors (GIST)
Build a cohort around your study
Share your indication, patient profile and required data. We’ll review tissue against your criteria.
Discuss sample quantities, matching and available clinical data with our team.
SUPPORTING DATA & SERVICES
Molecularly characterized TMAs & FFPE blocks
Use recorded molecular findings to select cases, or add characterization to matched tissue. The examples below describe our characterization offering; coverage varies by case and assay.
NGS characterization: variants, copy number changes & fusions
DNA hotspots
EGFR · BRAF · ERBB2 · AKT1
Copy number changes
MET · ERBB2 · FGFR1 · PTEN
Fusions
ALK · ROS1 · RET · NTRK1
Explore 38 genes across 3 alteration types
DNA hotspot examples
- AKT1
- AKT2
- AKT3
- ALK
- AR
- ARAF
- BRAF
- CDK4
- CDKN2A
- CHEK2
- CTNNB1
- EGFR
- ERBB2
- ERBB3
- ERBB4
- ESR1
- FGFR1
- FGFR2
- FGFR3
- FGFR4
- FLT3
- GNA11
- GNAQ
- GNAS
Copy number changes
- ALK
- AR
- CD274
- CDKN2A
- EGFR
- ERBB2
- ERBB3
- FGFR1
- FGFR2
- FGFR3
- KRAS
- MET
- PIK3CA
- PTEN
Fusion examples
- ALK
- AR
- BRAF
- EGFR
- ESR1
- FGFR1
- FGFR2
- FGFR3
- MET
- NRG1
- NTRK1
- NTRK2
- NTRK3
- NUTM1
- RET
- ROS1
- RSPO2
- RSPO3
Additional targets for tissue characterization
Selected examples: HER2 · TROP2 · Nectin-4 · PD-L1 · Mesothelin
View all listed tissue targets
- CD142 (TF)
- AXL
- EphA2
- 5T4
- LAMP1
- CanAg
- Integrin αv
- HER3
- Mesothelin
- FGFR2
- MET (HGFR)
- Nectin-4
- EGFR
- c-KIT
- HER2
- EGFRvIII
- CEACAM5
- TROP2
- PD-L1
- CD3
- CD8
Discuss the marker, tumor type and scoring requirements with our team. Existing results and any additional assay work are reviewed separately for the proposed cohort.
IHC control tissue: positive and negative FFPE control blocks
Choose IHC controls for antibody validation by the status of the marker your assay measures: a mutation, fusion or protein-expression target. Positive and negative control tissue is selected around your target. Control material is supplied as FFPE blocks. Tumor or normal tissue alone does not establish positive or negative status for that target.
Tell us the target and assay method, tissue type, required control status, format and quantity. Our team will review existing characterization and any additional screening needed.
- EGFR exon 19 / 21 variants
- KRAS G12A / C / D / V / R / S
- ALK / RET / ROS1 fusions
- PD-L1 / PD-1 expression
SUPPORTING DATA & SERVICES · MATCHED SAMPLES
Matched FFPE tissue & blood-based samples
Connect tissue findings with circulating biomarkers through collection-specific paired samples.
Tissue and blood from the same donor
Explore paired FFPE tissue and double-spun plasma or whole-blood collections across lung, colorectal, gastric, renal, esophageal, endometrial and ovarian cancers, and melanoma.
Explore plasma collections- Paired materials
- FFPE tissue + double-spun plasma or whole blood
- Collection source
- Ukraine
- Clinical context
- This paired collection does not include outcome data.
- Availability
- Request current sets, volumes and collection details for your study.
SUPPORTING DATA & SERVICES · IMAGES
Whole-slide images linked to tissue and clinical data
Connect tissue morphology to clinical context. Explore H&E whole-slide images with matched archived FFPE tissue and anonymized donor records for computational pathology and translational research.
Scanned in house on Aperio GT450 and AT2 scanners at 40×, with .svs files and review of slides and images by medical pathologists.
Explore Image & Clinical Data
Assays & pathology support
Integrated tissue assay services
Pair selected FFPE tissue and TMAs with assays and pathology guidance, planned around your study.
Protein expression
IHC assay services
Add protein-expression measurements with 100+ optimized IHC assays, or discuss assay development for a new target.
Explore IHC servicesSpatial RNA expression
RNAscope RNA-ISH
Localize target RNA in FFPE tissue, with pre-qualified samples, assay controls and pathologist scoring.
Explore RNAscopeMultiplex protein imaging
Multiplex immunofluorescence
Study protein co-expression, cell phenotypes and spatial relationships in selected FFPE tissue and TMAs.
100+ optimized IHC assays
Selected targets from the IHC library. Multiplex panels are reviewed separately.
Browse the IHC target library →Add IHC or RNAscope to this inquiry, and we'll plan the staining around your tissue. Request staining when you submit your tissue inquiry.
IHC staining on Ventana and Dako platforms. Review and scoring by medical pathologists with pharmaceutical industry experience.
Work with our experienced scientific team to tailor biospecimens, data, and integrated services to your research needs.
Our approach begins with our customers’ science.
We focus our acquisition on patient cohorts that meet the needs of biopharma, clinical, and translational researchers.
Plan your study
Tell us the FFPE cohort your study needs
Share your indication, stage, treatment and biomarker criteria, number of cases, specimen format and required data. We’ll review the available tissue and cohort options with you.